Repligen | RGEN - Debt


Repligen reported $533.72M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Agilent USD 3.41B 640M Jun/2025
Align Technology USD 121.27M 1.75M Sep/2025
Bio Techne USD 260M 40M Dec/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Bruker USD 2.44B 321.5M Jun/2025
Charles River Laboratories USD 2.79B 74.83M Jun/2025
Danaher USD 18.42B 1.56B Dec/2025
Dentsply International USD 2.49B 159M Jun/2025
Exact Sciences USD 2.34B 15.24M Sep/2025
General Electric Aerospace USD 20.49B 344M Dec/2025
Henry Schein USD 3.36B 2.21B Jun/2025
Illumina USD 2.6B 137M Jun/2025
IQVIA Holdings USD 14.96B 533M Sep/2025
Mettler Toledo International USD 2.18B 109.83M Jun/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pfizer USD 60.85B 78M Sep/2025
Repligen USD 533.72M 149.97M Jun/2025
Revvity USD 3.37B 5.86M Sep/2025
Standard Biotools USD 27.39M 1.23M Sep/2025
Thermo Fisher Scientific USD 35.68B 451M Sep/2025
Waters USD 1.54B 36.51M Jun/2025
West Pharmaceutical Services USD 202.7M 100K Sep/2025